You are here

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression

 

Online download statistics by month:

Online download statistics by month: September 2022 to July 2025

AbstractFullPdf
Sep 202211761197331
Oct 2022560569158
Nov 2022399400248
Dec 2022263268105
Jan 2023377379131
Feb 2023333336149
Mar 2023310314118
Apr 202321021192
May 2023231232115
Jun 2023244248102
Jul 2023328329130
Aug 202333033399
Sep 202322522673
Oct 202318718772
Nov 2023239241109
Dec 202323623766
Jan 202416316468
Feb 202417017158
Mar 2024231232104
Apr 202416716766
May 202424724758
Jun 202416116358
Jul 202421922048
Aug 202418618840
Sep 202419319433
Oct 202426026087
Nov 202421722249
Dec 202414414752
Jan 202515215252
Feb 202515615647
Mar 202521721867
Apr 202519219427
May 202511211334
Jun 202511211225
Jul 2025110
Total894890283071